Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 7 | 2023 | 546 | 2.070 |
Why?
|
| Internet | 6 | 2020 | 448 | 1.680 |
Why?
|
| Physician-Patient Relations | 6 | 2023 | 399 | 1.540 |
Why?
|
| Text Messaging | 2 | 2023 | 76 | 1.490 |
Why?
|
| Electronic Mail | 3 | 2020 | 45 | 1.230 |
Why?
|
| Physicians | 4 | 2019 | 440 | 1.100 |
Why?
|
| Blogging | 2 | 2017 | 11 | 1.020 |
Why?
|
| Hospitalists | 1 | 2023 | 37 | 0.820 |
Why?
|
| Medical Informatics | 2 | 2020 | 67 | 0.810 |
Why?
|
| Patient Portals | 2 | 2019 | 47 | 0.770 |
Why?
|
| Transgender Persons | 1 | 2022 | 62 | 0.720 |
Why?
|
| Patient Participation | 2 | 2019 | 216 | 0.620 |
Why?
|
| Cell Phone Use | 1 | 2018 | 1 | 0.600 |
Why?
|
| Consumer Health Informatics | 1 | 2017 | 1 | 0.570 |
Why?
|
| Social Media | 2 | 2019 | 116 | 0.540 |
Why?
|
| Video Recording | 1 | 2017 | 126 | 0.530 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 551 | 0.530 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 110 | 0.520 |
Why?
|
| Pharmacies | 1 | 2016 | 34 | 0.500 |
Why?
|
| Health Behavior | 2 | 2018 | 452 | 0.480 |
Why?
|
| Consumer Health Information | 1 | 2014 | 36 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 705 | 0.450 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 453 | 0.430 |
Why?
|
| Value-Based Purchasing | 1 | 2013 | 8 | 0.430 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 98 | 0.390 |
Why?
|
| Prescription Drugs | 1 | 2012 | 47 | 0.390 |
Why?
|
| Humans | 29 | 2025 | 59389 | 0.380 |
Why?
|
| Adult | 12 | 2023 | 15683 | 0.380 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2516 | 0.360 |
Why?
|
| Primary Health Care | 1 | 2016 | 648 | 0.350 |
Why?
|
| Medication Adherence | 4 | 2013 | 241 | 0.340 |
Why?
|
| Male | 15 | 2023 | 27747 | 0.310 |
Why?
|
| Quality Improvement | 1 | 2013 | 418 | 0.310 |
Why?
|
| Female | 15 | 2023 | 30724 | 0.290 |
Why?
|
| Hospitals | 2 | 2022 | 378 | 0.290 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 266 | 0.280 |
Why?
|
| Drug Costs | 3 | 2013 | 54 | 0.270 |
Why?
|
| United States | 9 | 2019 | 7426 | 0.260 |
Why?
|
| Qualitative Research | 2 | 2022 | 619 | 0.240 |
Why?
|
| Consent Forms | 1 | 2025 | 15 | 0.240 |
Why?
|
| Informed Consent | 1 | 2025 | 138 | 0.220 |
Why?
|
| Insurance Coverage | 3 | 2013 | 99 | 0.220 |
Why?
|
| Indiana | 2 | 2020 | 19 | 0.210 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2380 | 0.210 |
Why?
|
| Fasting | 1 | 2022 | 48 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 515 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2022 | 66 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 62 | 0.190 |
Why?
|
| Drugs, Generic | 2 | 2012 | 16 | 0.190 |
Why?
|
| Gender Identity | 1 | 2022 | 62 | 0.190 |
Why?
|
| Middle Aged | 11 | 2022 | 16314 | 0.180 |
Why?
|
| Emotions | 1 | 2023 | 215 | 0.180 |
Why?
|
| Drug Utilization | 2 | 2012 | 208 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2022 | 129 | 0.180 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2011 | 19 | 0.180 |
Why?
|
| Focus Groups | 1 | 2022 | 288 | 0.170 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 36 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 135 | 0.170 |
Why?
|
| Professionalism | 1 | 2019 | 10 | 0.170 |
Why?
|
| Uncompensated Care | 2 | 2009 | 5 | 0.160 |
Why?
|
| Aged | 9 | 2022 | 13406 | 0.160 |
Why?
|
| Medical Assistance | 2 | 2009 | 10 | 0.160 |
Why?
|
| Financing, Organized | 2 | 2009 | 16 | 0.160 |
Why?
|
| Inventions | 1 | 2019 | 3 | 0.160 |
Why?
|
| Attitude | 1 | 2019 | 96 | 0.160 |
Why?
|
| Young Adult | 5 | 2022 | 4272 | 0.160 |
Why?
|
| Trust | 1 | 2019 | 67 | 0.160 |
Why?
|
| Adolescent | 5 | 2022 | 5838 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 263 | 0.150 |
Why?
|
| Health Personnel | 1 | 2022 | 342 | 0.150 |
Why?
|
| Urban Population | 1 | 2019 | 180 | 0.150 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 60 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 413 | 0.140 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 861 | 0.140 |
Why?
|
| Personality Disorders | 1 | 2017 | 19 | 0.140 |
Why?
|
| Rural Population | 1 | 2019 | 188 | 0.140 |
Why?
|
| Personality | 1 | 2017 | 25 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 204 | 0.140 |
Why?
|
| Cost Sharing | 2 | 2013 | 14 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 342 | 0.130 |
Why?
|
| Disclosure | 3 | 2011 | 51 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 742 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 142 | 0.120 |
Why?
|
| Health Care Reform | 2 | 2013 | 85 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 601 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 186 | 0.120 |
Why?
|
| Health Expenditures | 2 | 2013 | 116 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 330 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 789 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2016 | 484 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2017 | 717 | 0.110 |
Why?
|
| Anxiety | 1 | 2017 | 387 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 725 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 64 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 54 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 371 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 308 | 0.100 |
Why?
|
| Cost Control | 1 | 2012 | 24 | 0.100 |
Why?
|
| Drug Industry | 2 | 2009 | 39 | 0.100 |
Why?
|
| Publications | 1 | 2011 | 28 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2011 | 36 | 0.090 |
Why?
|
| Developing Countries | 1 | 2011 | 86 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 57 | 0.090 |
Why?
|
| Health Resources | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 98 | 0.090 |
Why?
|
| Depression | 1 | 2017 | 829 | 0.090 |
Why?
|
| Quality of Life | 1 | 2017 | 1137 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2010 | 88 | 0.080 |
Why?
|
| Voluntary Health Agencies | 1 | 2009 | 4 | 0.080 |
Why?
|
| Seizures | 1 | 2010 | 113 | 0.080 |
Why?
|
| Financing, Government | 1 | 2009 | 30 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1231 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 81 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 168 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 527 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 192 | 0.070 |
Why?
|
| Comprehension | 1 | 2025 | 131 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 59 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2009 | 720 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 440 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 137 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5119 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2021 | 86 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 238 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 451 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 263 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 461 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 445 | 0.040 |
Why?
|
| Beneficence | 2 | 2009 | 4 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2019 | 10 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 442 | 0.040 |
Why?
|
| Culture | 1 | 2018 | 73 | 0.040 |
Why?
|
| Racism | 1 | 2019 | 81 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 297 | 0.040 |
Why?
|
| Neuroticism | 1 | 2017 | 2 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 259 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1166 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1597 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 426 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 71 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2338 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 151 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2012 | 45 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 52 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2011 | 9 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 364 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 46 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 17 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 23 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 292 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 144 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 147 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5281 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 211 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 202 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 163 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2011 | 52 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 16 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1051 | 0.020 |
Why?
|
| Altruism | 1 | 2009 | 13 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2009 | 23 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 76 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2009 | 35 | 0.020 |
Why?
|
| Government Regulation | 1 | 2009 | 40 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 4986 | 0.020 |
Why?
|
| Income | 1 | 2009 | 157 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 746 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 678 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 2375 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 1925 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6071 | 0.010 |
Why?
|